Free Access
Med Sci (Paris)
Volume 30, Novembre 2014
2e colloque de l’ITMO Santé publique – Médecine « personnalisée » et innovations biomédicales : enjeux de santé publique, économiques, éthiques et sociaux (Paris, 5 décembre 2013)
Page(s) 23 - 26
Section Session 2. Échanges Nord-Sud et innovations biomédicales
Published online 17 November 2014
  1. Thiébaut R, Hejblum B, Richert L. L’analyse des Big Data en recherche clinique. Rev Epidemiol Sante Publ 2014 ; 62 : 1–4. [CrossRef] [Google Scholar]
  2. Chakravarti A. Genomics is not enough. Science 2011 ; 334 : 15. [CrossRef] [PubMed] [Google Scholar]
  3. Laan MJ van der, Polley EC, Hubbard AE. Super learner. Stat Appl Genet Mol Biol 2007 ; 6 : 25. [Google Scholar]
  4. Pavlos R, Phillips EJ. Individualization of antiretroviral therapy. Pharmgenomics Pers Med 2012 ; 5 : 1–17. [PubMed] [Google Scholar]
  5. Raymond S, Delobel P, Izopet J. Phenotyping methods for determining HIV tropism and applications in clinical settings. Curr Opin HIV AIDS 2012 ; 7 : 463–469. [CrossRef] [PubMed] [Google Scholar]
  6. Ananworanich J, Gayet Ageron A, Braz M. Le, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006 ; 368 : 459–465. [CrossRef] [PubMed] [Google Scholar]
  7. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996 ; 271 : 1582–1586. [CrossRef] [PubMed] [Google Scholar]
  8. Drylewicz J, Commenges D, Thiébaut R, et al. Maximum a posteriori estimation in dynamical models of primary HIV infection. Stat Commun Infect Dis 2012 ; doi : 10.1515/1948-4690.1040. [Google Scholar]
  9. Vergu E, Mallet A, Golmard JL. Available clinical markers of treatment outcome integrated in mathematical models to guide therapy in HIV infection. J Antimicrob Chemother 2004 ; 53 : 140–143. [CrossRef] [PubMed] [Google Scholar]
  10. Bertrand J, Treluyer JM, Panhard X, et al. Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART. Eur J Clin Pharmacol 2009 ; 65 : 667–678. [CrossRef] [PubMed] [Google Scholar]
  11. Molina JM, Chêne G, Ferchal F, et al. The ALBI trial: A randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus. J Infect Dis 1999 ; 180 : 351–358. [CrossRef] [PubMed] [Google Scholar]
  12. Picard V, Angelini E, Maillard A, et al. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. J Infect Dis 2001 ; 184 : 781–784. [CrossRef] [PubMed] [Google Scholar]
  13. Molina JM, Levy Y, Fournier I, et al. Interleukin-2 before antiretroviral therapy in patients with HIV infection: A randomized trial (ANRS 119). J Infect Dis 2009 ; 200 : 206–215. [CrossRef] [PubMed] [Google Scholar]
  14. Guedj J, Thiébaut R, Commenges D. Maximum likelihood estimation in dynamical models of HIV. Biometrics 2007 ; 63 : 1198–1206. [CrossRef] [PubMed] [Google Scholar]
  15. Prague M, Commenges D, Drylewicz J, et al. Treatment monitoring of HIV-infected patients based on mechanistic models. Biometrics 2012 ; 68 : 902–911. [CrossRef] [PubMed] [Google Scholar]
  16. Iyengar R, Zhao S, Chung S-W, et al. Merging systems biology with pharmacodynamics. Sci Transl Med 2012 ; 4 : 126ps7. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.